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Abstract 12 
Background: In endemic area, schistosomiasis causes both overt and subclinical disease in 13 
young children and their mothers, as well as in returned travellers.   14 
Sources of data: Key recently published literature. 15 
Areas of agreement: An action plan for paediatric schistosomiasis and female genital 16 
schistosomiasis (FGS) is needed with expanded access to praziquantel (PZQ) required. 17 
Areas of controversy: Schistosomiasis-related morbidity is underappreciated. Present and 18 
future demand for PZQ treatment is bottlenecked, imbalanced and inequitable. Current 19 
dosing, treatment algorithms and access plans are sub-optimal with treatment stalled during 20 
pregnancy in antenatal clinics.   21 
Growing points: Raised dosing of PZQ (> 40 mg/kg) is being explored in young children. 22 
Surveillance of female genital schistosomiasis (FGS) is increasing. Use of PZQ in pregnancy 23 
is safe and guidelines for preventive chemotherapy are being revised in morbidity- and 24 
transmission-control settings.    25 
Areas timely for developing research: Shifting focus of population-level control to individual-26 
case management. Detection and prevention of FGS integrating PZQ delivery in child and 27 
women health services and antenatal clinics. Feasibility studies assessing alternative and 28 
expanded access to PZQ treatment to at-risk children and mothers and pregnant women. 29 
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Introduction  37 
Schistosomiasis is a water-borne disabling parasitic disease responsible for over 3.3 million 38 
disability adjusted life years (DALY) worldwide. 1 This figure is underestimated and in process 39 
of upward revision in more recent burden of disease studies. 2 Over 700 million people are at- 40 
risk of acquiring an infection with any of the most relevant Schistosoma species and these 41 
giving rise to two major clinical syndromes: 1- Intestinal schistosomiasis, caused by S. 42 
mansoni (South America and sub-Saharan Africa (SSA)) and S. japonicum (China, 43 
Philippines), and 2- Urogenital schistosomiasis caused by S. haematobium (SSA).  Of the 44 
currently recognised neglected tropical diseases caused by parasitic helminths3, 45 
schistosomiasis can be considered unique as being the sole water-borne parasite able to 46 
infect humans by per-cutaneous transmission4. Acute schistosomiasis, most commonly 47 
asspociated with S. japonicum, is an infrequent manifestation of the disease and is also known 48 
as ‘Katayama fever’, clinically presenting as a serum-sickness like syndrome. 5 More common 49 
chronic manifestation of all types of schistosomiasis result from egg-deposition in target 50 
organs and subsequent fibrosis impairing normal function. Less specific but more widely seen 51 
clinical characteristics are those derived from the pro-inflammatory response triggered by the 52 
parasite. These affect mostly children that are infected as early as infancy,6 and include 53 
anaemia of inflammation, impaired linear growth, decreased physical fitness and decreased 54 
quality of life. 7 Disease recognition is often overlooked and underappreciated, particularly  in 55 
younger children with early stages of schistosomiasis, as clinical features are shared and 56 
masked with other endemic diseases such as malaria. 4 Recognition of all disease stages by 57 
low-level skilled health workers is currently lacking and represents a hurdle to increase 58 
praziquantel (PZQ) treatment coverage beyond community-based control programmes, the 59 
mainstay of schistosomiasis control. A recent schistosomiasis clinical staging algorithm to aid 60 
diagnosis in low-resource settings has recently been published. 8  61 
Without anthelminthic treatment with PZQ, adult schistosomes may live for decades 62 
within the host.9  By contrast, juvenile worms are tolerant to PZQ making this drug an imperfect 63 
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treatment tool against acute infection, which is difficult to diagnose unequivocally even with 64 
modern biomarkers of infection10. On the other hand, as schistosome worms increase in 65 
number, pair and mature to lay eggs subsequently through time, the diagnostic patency of 66 
chronic schistosomiasis becomes ever more apparent; as does the congruency of a variety of 67 
serological, molecular or parasitology methods11. Using a selection of these markers it is 68 
possible to monitor the efficacy of PZQ treatment11 for which there are WHO guidelines that 69 
measure the proportional reduction of schistosome eggs in excreta before and after treatment. 70 
On the whole, the performance of PZQ is adequate according to those WHO standard 71 
measures of cure.12 However, measures of drug efficacy are poorer in younger children13 and 72 
across all ages in high prevalence and transmission environments14.      73 
Infected and overlooked 74 
Children and mothers in the endemic setting  75 
The endemic transmission landscape of schistosomiasis is typically over-dispersed or focal 76 
such that the disease can be very concentrated geographically around a given freshwater 77 
habitat, while others nearby may experience no disease at all15. In such an area, e.g. a rural 78 
village where there this schistosomiasis, the patency of infection varies by age and gender4. 79 
Using traditional diagnostic methods based on egg-detection the most obvious infected group 80 
are children, of either gender, in their late childhood and early adolescence4. This has been 81 
the ‘classic’ view of the epidemiology of schistosomiasis in an endemic setting for many years 82 
as shown in Figure 1A and discussed by Peter Jordan in this journal some 45 years ago16. 83 
However since that time, a more extensive knowledge and appreciation of schistosomiasis 84 
has been developed, now seen as a complex disease that may or may not coincide with 85 
present egg-patent infection.2 The traditional view based on egg-patency in the excreta gave 86 
rise to the commonly held assumption that only heavy egg-patent infections were important 87 
and those of light or moderate could be ignored17.  This view is largely incorrect; if alternative 88 
diagnostic methods are used such as serology or biomarkers, schistosomiasis is much more 89 
pervasive in mothers and young children than previously thought18. Using a combination of 90 
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diagnostic assays has helped to better reveal the burden of disease in pre-school-aged 91 
children and their mothers19.  But it’s not only improved diagnostic accuracy for Schistosoma 92 
detection, morbidity detection methods have also been refined and thus schistosomiasis 93 
encompasses not only the chronic manifestations related to end-organ fibrosis (portal 94 
hypertension due to periportal fibrosis, bladder polyps and squamous cell carcinoma of the 95 
bladder), but it now includes more functional morbidities such as anaemia and arrested linear 96 
growth that are reversible only if treated early in childhood. The inputs used for the global 97 
Burden of Disease 2010 study underestimated the burden of the disability associated with 98 
Schistosoma infection.20 These estimates did also not include late effects of the functional 99 
morbidities, of which growth stunting and cognitive impairment, infertility, dyspareunia and 100 
genital disease are now widely recognised as schistosomiasis-associated morbidities. 101 
Therefore the concept of an asymptomatic disease, historically describing children without 102 
overt clinical signs and symptoms, with no obvious chronic manifestations, can no longer be 103 
accepted. 2 104 
Figure 1: A schematic of (A) prevalence by age inferred by egg-count versus serology across 105 
an endemic population (i.e. in mothers and their children’s) and (B) visual detection of 106 
antibodies to soluble eggs antigen (SEA) in mothers (M) and children (C) from lakeshore 107 
village on Lake Albert, Uganda. Positive (+) and negative (-) controls indicated. 108 
 109 
 110 
 111 
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There is an essential environmental transmission dynamic, as part of the schistosome 112 
lifecycle, which is determined by the immediate presence of permissive freshwater snail hosts 113 
and by unsafe water contact activities undertaken by the surrounding community, albeit from 114 
local or visiting people. In principle, water contact can be broken down into two partially related 115 
components, contamination- and exposure-related activities21. The transmission epidemiology 116 
of schistosomiasis is intricately interwoven with the daily need for water as part of socio-117 
economic development and environmental hygiene. Until recently, as younger children are 118 
often not directly seen in water, it was thought that their risk of infection was low and largely 119 
in accordance with a low prevalence of egg-patent infection. However, this appraisal was 120 
overturned as it is largely by passive water contact, such as being bathed in water collected 121 
by the mother, often away from view within the homestead, that infants becomes first infected. 122 
Such infections are best detected by serological methods. Figure 1B and data from novel 123 
studies using global position system data suggest the levels of unsafe water contact of infants 124 
and pre-school-aged children can be alarmingly high18, 22. Furthermore, there is increasing 125 
concern about the importance of maternal schistosomiasis23 such that the disease should be 126 
tackled simultaneously in both child and mother.    127 
Children and mothers within travel medicine 128 
Schistosomiasis is also a travel related disease for those that visit disease endemic locations 129 
and knowingly or unknowingly undertake unsafe water contact activities. In the largest 130 
returned traveller cohort published in the UK, the most common presenting symptom was 131 
haematuria, related to urogenital schistosomiasis and almost half of the patients had 132 
eosinophilia. 24 A major difference in travel-related schistosomiasis is the age of the first 133 
infection, typically in adults who have had little, if any, prior exposure to any helminthiasis. 134 
This  allows use of more general immunological markers of infection e.g. eosinophilia 25. 135 
Similarly, with a detailed travel history, the exact time and duration of most likely exposure can 136 
be determined26, setting aside these rather singular events of the traveller from the inevitable 137 
daily routine of those that live in close proximity to unsafe water sources. The disease 138 
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spectrum that schistosomiasis also induces in travellers differs, typically with a greater number 139 
of cerebrospinal complications, largely owing to ectopic egg laying sites, necessitating 140 
advanced diagnostic imagery techniques and clinical management 27.  141 
It is interesting that significant disease can accrue in both young children and women 142 
with relatively short durations of exposure and infection28, 29. For example, there are numerous 143 
case reports of maternal schistosomiasis30 as well as individual cases where complications 144 
have arisen from egg-based lesions within the Fallopian tubes 30. Schistosomiasis within these 145 
patients has been typically detected spuriously, for example, upon surgical encounter rather 146 
than upon post-visit screening. In the UK, for example, there is no specific-screening 147 
programme for schistosomiasis, and diagnostic tests are only requested when there is clinical 148 
suspicion, however, awareness of the disease within general practice settings is typically low.  149 
In addition, many of these travellers present with low-intensity infections, and current 150 
diagnostics may be too insensitive for detection (egg counts in urine or stool). 24 Serology can 151 
not distinguish between acute or chronic infection, and cannot evaluate treatment efficacy due 152 
to persistent IgG. New antigen diagnostic tests, the Circulating Anodic Antigen (CAA), 153 
secreted across Schistosoma species is set to become a useful tool for low-level infections as 154 
it can detect as little as one worm pair. 31 155 
Pregnant travellers have seldom been reported in the literature. A recent retrospective 156 
case series from Israel reported adverse foetal outcomes including low birth weight, 157 
miscarriages and preterm labour, in pregnant women with schistosomiasis acquired during 158 
travel that had not received PZQ at any given time after Schistosoma exposure compared to 159 
those that had received PZQ during pregnancy and had normal birth outcomes. 29   160 
It is very plausible that many travellers returning to Europe will have schistosomiasis, 161 
which will continue to go undetected until clinical manifestations develop. A good example is 162 
the recent epidemic focus of urogenital schistosomiasis in Corsica that caught many general 163 
practice surgeries by surprise32. The first case of urogenital schistosomiasis caused by 164 
infection with S. haematobium in Corsica was observed in a 4-year old French child upon 165 
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presentation to Toulouse Hospital in March 2014 with a persistent history of haematuria. The 166 
father of the child and other relatives from France were also found to have chronic haematuria, 167 
pointing towards a then hitherto unknown S. haematobium transmission focus on the island. 168 
Since then there has been a concerted effort to describe and curtail the disease which has 169 
raised several concerns unique to this European setting and tourist destination32.   170 
Focus on female genital schistosomiasis (FGS) 171 
FGS is likely the most underestimated gynaecological disorder in the tropics. It manifests with 172 
egg entrapment in the genital mucosa with granuloma formation and neovascular changes. 33 173 
Pathognomonic lesions can be  visually seen by colposcopy, but this method is costly and 174 
requires high level training, frequently absent in endemic areas. A new visual diagnostic FGS 175 
pocket atlas is freely available from WHO (http://apps.who.int/iris/handle/10665/180863) and 176 
targeted to clinical health-care professionals and aiming to help with the identification of typical 177 
cervical lesions. The main limitation of this promising tool is the need for a colposcope to 178 
perform the gynaecological examination. 179 
FGS affects women that are or have been infected with S. haematobium at any given 180 
point in their lives. The exact onset of the lesions is unknown, as it is not ethically permissive 181 
to conduct studies in girls that have not had their sexual debut. However genital 182 
symptomatology has been linked to S. haematobium infection even in pre-pubertal girls, 183 
suggesting early onset of FGS 34The consequences of the diagnostic difficulties for FGS get  184 
reflected in the absence of accurate disease burden estimates in S. haematobium areas. This 185 
is particularly troublesome when there is strong evidence of a fourfold increase in HIV in 186 
women with Schistosoma infection.35, 36 The impact of FGS on women’s reproductive life is 187 
large with strong ties to infertility and subfertility. 30 37 Cervical fibrotic lesions remain largely 188 
unchanged months after PZQ treatment given following current recommended single-dose 189 
guidelines. 38 This distressing reality highlights the importance of early treatment to prevent 190 
established fibrotic morbidity.  191 
Current control of schistosomiasis with PZQ 192 
8 
 
The mainstay of schistosomiasis control relies on preventive chemotherapy (PC) with PZQ, a 193 
broad spectrum anti-parasitic drug delivered through mass drug administration programmes 194 
to school-aged children. Programme regularity relies on background Schistosoma spp. 195 
prevalence in each endemic country. PZQ is therefore delivered annually (egg-patent 196 
prevalence ≥ 50%), every two years (prevalence > 10-50 %) or twice during primary schooling 197 
time (prevalence ≥ 10%).39 In 2012, it was estimated that across the world some 249 million 198 
people were in need of regular PC, with 93% of those eligible to be found in sub-Saharan 199 
Africa40. Only 34% of all eligible school-aged children received PZQ in 2014. 41 200 
Bottlenecks in global supply and delivery of PZQ   201 
It has been noted across many nations,  and also formally reported, that Africa is desperate 202 
for PZQ42, especially given that some 100 million school-aged children are eligible for 203 
preventive chemotherapy43. Since the  development of PZQ in the 1970s, the large-scale 204 
production and access plan for this drug has undergone several revisions44, 45. The most 205 
significant perhaps, was the drop in price from $1.00 USD in 1998 to $ 0.08 USD in 2003 per 206 
tablet as then retailed by various pharmaceutical suppliers following from off-patent 207 
production46. This raw tablet price roughly equates to $ 0.20 USD per 40 mg/kg treatment for 208 
a typical school-aged child (i.e. 2.5 tablets) which also enabled simple per capita forecasting 209 
of its supply as well as likely distribution costs for treatment of school-aged children in school. 210 
This has been largely propelled forward by entities like the Schistosomiasis Control Initiative 211 
(SCI)47 operating since 2002. The SCI is a Bill & Melinda Gates Foundation project that has 212 
also helped to solidify national actions against other diseases amenable to preventive 213 
chemotherapy, for example, against  soil-transmitted helminthiasis with co-delivery of 214 
albendazole and PZQ to school-aged children using school-based logistical and delivery 215 
systems48.      216 
In 2007, a change in this landscape started to take place upon the first pledged 217 
donation gratis of PZQ to WHO by Merck-KGaA (Darmstadt, Germany) under their brand 218 
name of CesolTM. Over the 2007-2010 period, 20 million PZQ tablets were donated annually, 219 
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prequalified by WHO and then shipped in-country to those national control programmes 220 
requesting PZQ stocks for use in PC campaigns. Following on the London Declaration on 221 
NTDs (http://ntd-coalition.org) in 2012, the Merck-KGaA donation was pledged to expand and 222 
up-scale production to a total of 250 M tablets per year by 2020, achieving 103 M donated 223 
tablets in 2015.  224 
Since the London Declaration and the Merck-KGaA donation, the production market 225 
of PZQ has not been stable, with certain companies reducing or stopping their production. An 226 
unforeseen consequence of this is that the donation which is typically ring-fenced for use in 227 
school-aged children, is coming under increasing pressure to be used to shore-up access to 228 
PZQ in other groups. It is particularly noteworthy that the treatment needs of adults are not 229 
factored into the donation, and are largely catered for by Ministries of Health within their 230 
procurement of essential drugs.  231 
Expanded access for preventive chemotherapy and treatment to vulnerable 232 
populations 233 
Paediatric praziquantel formulation 234 
It is astonishing that the PZQ treatment needs of school-aged children had so long eclipsed 235 
those of younger, preschool-aged children  who today are considered just as vulnerable, if not 236 
more so, than their older counterparts45. As recently highlighted, this oversight is concomitant 237 
with a general neglect of paediatrics within tropical medicine.49  From today’s perspective, it is 238 
unethical to withhold safe medical treatment to those that need it, especially children. 239 
Importantly, PZQ has been safely delivered off-license through crushed tablets to hundreds of 240 
children under four years of age across different settings.50 The first pharmacokinetic-241 
pharmacodynamic study in young Ugandan children with S. mansoni infection using crushed 242 
tablets of PZQ found that raised dosing to 60 mg/kg was favourable to the WHO recommended 243 
single dosing of  40 mg/kg51 which was in contrast to results of a multi-country meta-analysis 244 
that only included school-age children52. Worryingly, no child achieved bloodstream antigenic 245 
clearance based on schistosome circulating anodic antigen (CAA). Given that many of these 246 
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children had very high levels of CAA before treatment, to remove this substantial worm burden 247 
would require repeated treatments51. 248 
Current control programmes unduly focus attention on school-aged children that 249 
harbour highest intensity egg-patent infection. This is further skewed by the fact that traditional 250 
diagnostic methods may miss moderate-light infections that are more commonly seen in the 251 
youngest children. 11 This approach downplays the clinical importance of these early infections 252 
that require more sensitive diagnostic methods.53, 54 Ultrasound detectable morbidity is already 253 
present in children and lesions responds to higher PZQ doses. 55 254 
 Over the last decade with a greater focus on disease surveillance in children under 255 
five years of age, there is a much wider appreciation of their treatment needs18, 50. Addressing 256 
this, in 2010 WHO held an informal review of the available evidence for treating preschool 257 
aged children (PSAC) with schistosomiasis. The recommendations of this meeting concluded 258 
that it was possible to use crushed or broken tablets for treatment in the interim until a children-259 
friendly paediatric formulation of PZQ was developed. In response, a public-private-260 
partnership was formed in July 2012 and entitled the paediatric praziquantel consortium 261 
(PPC). This was tasked to develop, register and provide an oral dispersible tablet (ODT) for 262 
use in future treatment campaigns to supplement the existing Cesol ® 600 mg tablet donation. 263 
56 264 
 Several important decisions first had to be addressed in the development of an 265 
appropriate PZQ formulation, its optimal dosing and associated product access plan. Results 266 
from ongoing bioavailability studies in the PPC were presented at an additional meeting of the 267 
WHO in September 2015 to further assess treatment needs and guidelines for PSAC. 56, 57 268 
The optimal delivery platform to roll-out this new paediatric formulation has yet to be evaluated. 269 
As a feasible product delivery plan, PSAC PZQ preventive treatment could be integrated within 270 
the ongoing maternal-child health visits as part of the integrated management of childhood 271 
illnesses (IMCI), a comprehensive primary health care delivery plan endorsed by WHO. 17 272 
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PZQ in pregnancy  273 
An estimated 40 million women of reproductive age are infected with Schistosomiasis.  At the 274 
time of its release in 1979, PZQ was never formally studied in pregnant or lactating women 275 
and remains a United States Federal Drug Administration pregnancy Class B drug. Its Class 276 
B designation was based on numerous animal studies supporting its safety,58, 59 but a lack of 277 
well-controlled trials during human pregnancy. 60 278 
In 2002, the World Health Organization (WHO) sponsored an “Informal Consultation” 279 
on the use of PZQ during pregnancy and lactation. The report emanating from that meeting 280 
recommended that all schistosomiasis infected pregnant and lactating women be considered 281 
high-risk groups and offered treatment with praziquantel individually or during treatment 282 
campaigns.61-63 This recommendation was reissued in 2006 as part of the WHO’s Guidelines 283 
for Preventative Chemotherapy for Helminthiasis 39 in which it was recommended that 284 
pregnant and lactating women be included in mass drug administration (MDA) campaigns. 285 
39Importantly, at the time of these reports, no randomized controlled trials of praziquantel 286 
during human pregnancy had been conducted. Addressing the safety of expanded use, the 287 
authors cited demonstrated PZQ’s safety in animal models, post-market surveillance data, 288 
and PZQ use for the treatment of cysticercosis during pregnancy. With respect to efficacy, the 289 
recommendations were based on both demonstrated reversibility of end organ damage and 290 
anemia with more frequent treatment, among non-pregnant populations. Many nations did not 291 
initially adopt these guidelines citing lack of sufficient safety data from controlled trials.  292 
Praziquantel and human pregnancy: results of two randomized controlled trials (RCTs) 293 
Two randomized, double blind, placebo controlled trials have been completed since the most 294 
recent WHO Guidelines addressing the treatment of pregnant women with PZQ. 64, 65One 295 
randomized, controlled trial conducted in Uganda, assigned women attending a hospital-296 
based antenatal clinic into one of four groups: placebo, albendazole, praziquantel, or 297 
praziquantel + albendazole. The study agent(s) were given during the second or third trimester 298 
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(mean gestational age 26.6 weeks).64 This large trial did not demonstrate a significant impact 299 
of PZQ on maternal anemia or birth weight, even among the approximately 18% of women 300 
who were infected with S. mansoni.   301 
A second RCT, conducted in Leyte, The Philippines, recruited only women who were 302 
infected with S. japonicum at the time of enrolment. Women (N=360) were treated at 12-16 303 
weeks gestation with 60 mg/kg of Praziquantel given as a split dose over 4 hours or placebo. 304 
PZQ did not significantly impact the primary outcome, birth weight, nor other secondary 305 
outcomes including prevalence of low birth weight, prematurity, and intra-uterine growth 306 
restriction. PZQ treatment did culminate in increased maternal serum ferritin levels at 32 307 
weeks gestation with a trend toward improved new born iron endowment. In addition, pregnant 308 
women were successfully treated as defined by parasitological cure at 22 weeks gestation.  309 
Treatment was well tolerated with reactogenicity rates similar to that observed in non-pregnant 310 
subjects. Importantly, there were no significant differences in key safety outcomes including 311 
abortion, foetal death in utero and congenital anomalies.  65 312 
Policy implications/Future Directions  313 
Though some nations, reassured by results of RCTs, have recently adopted recommendations 314 
to include pregnant women in PZQ MDA campaigns,64, 65 many nations still have not. 66For 315 
example, in Zanzibar, where local guidelines did not recommend treatment of pregnant 316 
women, two of the most commonly reasons cited by individuals for not receiving PZQ  during 317 
community treatment campaigns were pregnancy and breast feeding.67 Furthermore, there is 318 
concern that even in nations that have adopted these recommendations, limited dissemination 319 
of information to schistosomiasis program managers and health care providers has led to 320 
continued exclusion. Across these nations, millions of women of reproductive age are not 321 
treated for many years during repeated cycles of pregnancy and lactation. An unfortunate 322 
implication of this creates an obvious refugia for schistosomes within the human populace 323 
ultimately facilitating environmental transmission.   324 
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Conclusions 325 
The exclusion of two of the most vulnerable infected populations (pregnant women, PSAC) 326 
from schistosomiasis control programmes is detrimental not only to their own health present 327 
and future, but it also precludes the elimination of this parasitic disease in endemic areas. This 328 
inequality is also reflected in the research effort dedicated to these groups as shown in Figure 329 
2. There is a disproportionate amount of evidence derived from other aspects of 330 
schistosomiasis in detriment of PSAC and pregnancy data, notwithstanding returned 331 
travellers. Paradigm shifts are not only needed to acknowledge light infections as pernicious 332 
to health and moving away from heavy worm burdens as the only accurate morbidity indexes. 333 
It is also indispensable to think of alternative PZQ delivery platforms to target at-risk 334 
populations that can synergise with ongoing MDA efforts. One model could include PZQ 335 
delivery at antenatal clinics and maternal-child health visits.  336 
Some interventions that can help address these issues include education to programme 337 
managers in endemic regions that lead MDA campaigns on the safety of PZQ in pregnancy. 338 
Clinical officers and nurses in clinics can be educated on the safe delivery of PZQ in PSAC.  339 
In addition, women, who have been told for decades that they cannot be treated when 340 
pregnant or breast feeding, will likely need targeted re-education. Finally, co-authors of the 341 
Philippines RCT and regulatory program staff at the United States’ (US) National Institutes of 342 
Health/National Institute of Allergy and Infectious Diseases, are collaborating with the US 343 
Federal Drug Administration to change PZQ’s class designation from B to A, indicating safe 344 
use during human pregnancy as supported by well controlled studies. 345 
  Within the existing PZQ supply constraints the commitment from national control 346 
programmes has to expand its views and operate on an evidence-based agenda, without 347 
neglecting at-risk populations in need of treatment. It will take a coordinated effort between 348 
national and international agencies and strong advocacy to achieve this,  but the time is right 349 
to make these changes.   350 
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Figure legends 362 
 363 
Figure 1: A schematic of (A) prevalence by age inferred by egg-count versus serology across 364 
an endemic population (i.e. in mothers and their children’s) and (B) visual detection of 365 
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antibodies to soluble eggs antigen (SEA) in mothers (M) and children (C) from lakeshore 366 
village on Lake Albert, Uganda. Positive (+) and negative (-) controls indicated. 367 
 368 
Figure 2: Articles published and indexed in Pubmed in the last 10 years on schistosomiasis 369 
in pregnancy, children and preschool children. 370 
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